Toxicity Profile of eBAT, a Bispecific Ligand-Targeted Toxin Directed to EGFR and uPAR, in Mice and a Clinical Dog Model.
immunotoxin
pharmacology
sarcoma
targeted therapy
toxicity
Journal
Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765
Informations de publication
Date de publication:
26 Aug 2024
26 Aug 2024
Historique:
received:
25
04
2024
revised:
15
07
2024
accepted:
20
08
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
27
9
2024
Statut:
epublish
Résumé
EGFR-targeted therapies are efficacious, but toxicity is common and can be severe. Urokinase type plasminogen activator receptor (uPAR)-targeted drugs are only emerging, so neither their efficacy nor toxicity is fully established. Recombinant eBAT was created by combining cytokines EGF and uPA on the same single-chain molecule with truncated
Identifiants
pubmed: 39330834
pii: toxins16090376
doi: 10.3390/toxins16090376
pii:
doi:
Substances chimiques
Receptors, Urokinase Plasminogen Activator
0
ErbB Receptors
EC 2.7.10.1
Antineoplastic Agents
0
Urokinase-Type Plasminogen Activator
EC 3.4.21.73
Epidermal Growth Factor
62229-50-9
Ligands
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : 1K01TW171420-23A1
Pays : United States